When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ZLAB - Zai Lab commences late-stage study of retifanlimab in lung cancer
Zai Lab Limited
The first participant has been dosed in a China-based Phase 3 clinical trial, PODIUM-304, evaluating Zai Lab Limited (ZLAB) and Incyte's (INCY) PD-1 inhibitor retifanlimab, combined with platinum-based chemo, in treatment-naïve patients with metastatic non-small cell lung cancer ((NSCLC)).The primary endpoints of the 530-subject study are overall survival and progression-free survival. The estimated primary completion date is August 2024.